- Main navigation
- CLIC & The CTSA Program
- News & Events
- Groups
- Common Metrics Initiative
- Education & Career Development
- Collaboration
- Resources
- CTSA Program Projects & Initiatives
- Contact
- Search
Learn what it takes to make your surveys as efficient as possible. Customize survey settings, manage survey participants, and stay up-to-date on survey progress and results
Learn how to build reports and view/export your project data/results in just a few steps!! You can also use the interactive Data Import tool is used to upload data from a comma-delimited (CSV) file, into your REDCap project. Instead of entering records one by one, you can use the import tool to upload multiple records at once.
This module describes the study-level documentation expected at Duke. It describes the regulatory binder, documents required for all studies, documents required for most studies, and documents that are required depending on the type of study. It discusses standard operating procedures. This module provides guidance for creating the binder or file, maintaining central files, and what should not be
This training provides information regarding the sponsor and investigator requirements for an IND or IDE as well as resources to ensure compliance with FDA regulations. There are two separate training modules that each focus on the requirements for the specific regulatory application that the sponsor or sponsor-investigator holds. Sponsors who hold an IND (for drugs and biologics) can complete the
Focal and Segmental Glomerulosclerosis, Minimal Change Disease and Membranous Nephropathy, presenting as Nephrotic Syndrome (NS), are a group of rare renal diseases that may cause serious complications and end-stage kidney disease, generating significant individual, societal and economic burdens. The Nephrotic Syndrome Study Network (NEPTUNE) brings together physician scientists at 26 sites in the
Myasthenia gravis (MG) is an autoimmune disease that blocks the signal from nerve to muscle, producing weakness. The nature of the disease can range from isolated severe vision problems, like drooping eyelids or double vision, to profound general weakness leading to breathing muscle failure. Although the cause of MG is not known, the disease appears to vary based on the types of antibodies
Lysosomal disorders (LD) are a group of approximately 70 inherited metabolic conditions resulting from defects in lysosomal function; usually deficiency of a single enzyme required for the metabolism of lipids, glycoproteins, or mucopolysaccharides. Collectively, LD are not especially rare; estimates suggest that approximately 1 in 5,000 newborns will be affected with one identified LD
Amyotrophic lateral sclerosis (ALS) is a fatal disease that involves progressive death of motor nerves in the brain, brainstem and spinal cord. The disease is closely related to disorders such as primary lateral sclerosis, hereditary spastic paraplegia, progressive muscular atrophy and frontotemporal dementia. These diseases have shared genetic causes and underlying biology. They also have in
The Brain Vascular Malformation Consortium (BVMC) focuses on three rare brain conditions: familial cerebral cavernous malformation (CCM), Sturge-Weber syndrome (SWS), and hereditary hemorrhagic telangiectasia (HHT). These disorders are poorly understood, are costly to manage, and can cause serious complications such as hemorrhages, seizures, and problems with spinal cord, nerve or brain function
The National Institutes of Health (NIH) awarded a research team at George Washington (GW), Yale, and Duke Universities $7.8 million to establish a rare disease network for Myasthenia Gravis.
The Duke CTSA KL2 program was recently identified as one of the top program hubs by the Center for Leading Innovation and Collaboration (CLIC). The Duke KL2 program was a top performer in the KL2 education program – Underrepresented measure. The CLIC evaluates programs using a Common Metrics Initiative. In alignment with the CLIC’s current goals, the Duke KL2 program set a goal to increase the
Following the announcement of new FDA guidance on the conduct of clinical trials of medical products during the current COVID-19 pandemic, the Clinical Trials Transformation Initiative (CTTI) last week held a public call for experiences and insights from across clinical trials ecosystem. During this webinar, presenters will provide a summary of that aggregated feedback and offer best practices for
The modern era of health analytics is built on data science. Data science merges computer science with statistics, creating new potential for extracting clinical insight from the exponentially increasing “big” data relevant to our patients’ health. Realizing this potential requires new capabilities and innovative technologies. For effective implementation in a healthcare setting, an Accelerator is
The 11th Annual International Science of Team Science Conference is June 1-4, 2020 at Duke University in Durham, NC! SciTS 2020 will bring together team science practitioners, scholars, and providers from a broad range of disciplines to share and advance the latest evidence-based methods in team collaboration and transdisciplinary science. Speakers and attendees will include investigators
This training provides information regarding the sponsor and investigator requirements for an IND or IDE as well as resources to ensure compliance with FDA regulations. There are two separate training modules that each focus on the requirements for the specific regulatory application that the sponsor or sponsor-investigator holds. Sponsors who hold an IND (for drugs and biologics) can complete the